Company expects cash runway to last through end of calendar 2028
Grace Therapeutics plans NDA resubmission for GTx-104 when either manufacturing site reaches readiness
Company intends to use cash to address FDA CRL items and advance GTx-104
Result drivers
Impairment charge - Net loss increased due to full impairment of intangible assets for GTx-101 and GTx-102 after strategic deprioritization
Lower R&D expenses - Research and development costs fell as GTx-104 clinical trial and NDA submission completed in prior period
Lower admin costs - General and administrative expenses declined due to reduced pre-commercial planning for GTx-104
Key details and analyst coverage
Metric
Actual
Q1 loss per share
$0.91
Q1 net loss
$15.79 mln
Q1 pretax loss
$15.79 mln
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
GRCE•
